Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Int'l Northair commences first phase at El Tesoro
2004-03-08 08:29 ET - News Release
Mr. Fred Hewett reports
DRILL PROGRAM COMMENCES AT EL TESORO PROJECT
International Northair Mines has commenced a first phase initial drill program at the El Tesoro project, Durango state, Mexico. At El Tesoro, Northair controls a contiguous land package of approximately 1,000 hectares, with seven currently known gold-bearing zones occurring along a strike length of over 2.5 kilometres.
An approximate 2,000-metre, initial drill program is currently under way to test five of the seven known gold-bearing zones. A reverse circulation rig will complete approximately 15 holes distributed across the zones. The greatest focus during this phase will be on the A, B and E zones, with additional selective drill testing of the C and D zones. Results from this first program are expected within six weeks. In conjunction with the drill program, the company is continuing with an aggressive property exploration program which includes mapping, sampling and trenching of the lesser explored portions of the property; and completion of road access to the G zone.
Northair has taken more than 750 samples on the project to date, 190 of these taken from trenches. Highlights of hand trenching include three metres of 18.89 grams per tonne gold from the A zone and 10 metres of 9.00 g/t gold from the B zone. A recently completed mechanical trenching program successfully extended previously known zones of mineralization, exposing apparent full widths, and providing additional outcrops for geologic mapping band sampling. Examples of mechanical trenching results include six metres of 27.04 g/t gold and 702.2 g/t silver from the A zone, and three metres of 22.42 g/t gold and 72.0 g/t silver from the E zone. The current drill program is designed to establish the mineralized zones down dip continuity.
The exploration program is under the direction of Jim Robinson, vice-president of the company, who is a qualified person as defined by NI 43-101. Assaying to date has been performed by ALS Chemex Laboratories in Vancouver, B.C., with sample preparation at its facilities in Hermosillo, Mexico. Gold assays are performed on a 50-gram fire assay using an atomic AAS or gravimetric finish. The company maintains a quality control program in the preparation, shipping and checking of all samples from the property.
WARNING: The company relies upon litigation protection for "forward-looking" statements.
Somebody likes them. Nice break-out day.
some maps for INM A and E zone
http://www.northair.com/international/pop-eltesro-tm01.html
http://www.northair.com/international/pop-eltesro-tm02.html
http://www.northair.com/international/pop-eltesro-tm03.html
sadly not very readable to me
but what I can see is that they have not sampled across the mineralised zone. I wonder how they know it is there.
Yep. There aren't many shares available for sale. We should shoot up pretty good with some decent news.
Charts says, I'm going up to the next level. BWTFDIK.
INM has 10,000 shares bid at 1.24. I don't think I have ever seen a stock dip so many times and always come back and everytime it does I kick myself for not buying the dip.
There must be some good news coming...
minor GRUB then.
MUM bouncing nicely today - Timmins nickel play. Do you follow that one TF?
I have no idea why its called that. Good question.
but what the hick is GRUB stand for
A grub is a special number of posts like 55 100 10000 333 ...
Web site has been updated (long over due). Some nice pics of the trenching.
What's a GRUB? seen it enough times....
Interesting move the last couple of days. Maybe we'll hear about the G-zone soon.
EDIT: GRUB!
G spot 101 (...blush I just showed myself up). Now I remember, I withdrew early from that class to have a smoke.
erhm, I'll get my coat....
INTL. NORTHAIR MINES LTD. (INM : TSX-V : C$1.20) -
SPECULATIVE BUY -
12-MONTH TARGET PRICE: NA
Graeme Currie
Comment: International Northair reports additional high-grade Au/Ag trench values Yesterday, Northair reported the technical trench results from the next zone tested in this program - the E Zone. Results from this target, too, have confirmed previous chip sample grades. We understand that the trenching program will continue through February and that an initial drill program could be considered for a late February start date. Though no budget is yet set, we would assume that drilling of some 2000-3000 metres might be considered as a first phase. Though very early in its exploration stage, the El Tesoro prospect has already yielded some very encouraging surface values. The mechanical trenching results assist in removing some concerns relating to surface enrichment, and the values reported from the A and E Zones do provide further evidence of potential economic grades and thickness. Though a grassroots target, we consider the exploration potential as evidenced by results to date as positive. The exploration leverage provided by this junior, given the current market capitalization of Northair that is just over $15 million, appears to be very good. We rate the shares as a SPECULATIVE BUY for risk accounts only.
They cover it in first year mining tech. Basically it is a hand sampling technique done prior to drilling, somewhat easier to do in a wide trench. Here is the manual.
You haven't heard of that before? Its the spot that gets all the miners excited.
Thanks. Funny it was on Kitco first before the newswires?
Results were good but not enought to light a big fire I think. We'll see today.
Wayne
I beleive he said it would come last.
What a G spot? Is it a drilling term? (g)
Have they released any mechanical trenching results on the G zone?
Maybe the G zone is the G spot? (g)
my last chat with Fred, he mentioned the G zone being the one he liked. The grade is average but it is open in all directions.
Made me buy more.
Its a bit narrow but not too narrow and the grades are in line with the last results which were very good. The real story will be told when they drill.
Not long now.
well these results don't jump out at me. But the picture that is forming is looking very nice.
Wayne and Beanburger
http://www.kitco.com/pr/1251/article_01122004135030.pdf
The release is on kitco. Its a PDF so I can't paste it to here.
You have a link to this PR?
Wayne
Apparently it was emailed but I'm not on the company's list. I don't see it on the newswires yet.
can't make sense of those results posted, now where's the NR.
Luckly I bought more today.
The grades look fairly consistent. Bring on the drills!
NEW TRENCHING RESULTS RECEIVED FROM EL TESORO A and E ZONES
International Northair Mines Ltd. (TSXV:INM) has received the second set of mechanical trenching results from the El TesoroProject, Durango State, Mexico. At El Tesoro, Northair controls a contiguous land package of approximately 1000 hectares, covering 7 currently known gold bearing zones. (See Company Website for maps and photos). Previous sampling of these zones by the Company has returned significant gold values over appreciable widths. Northair has taken more than 750 samples on the project to date, 190 of these taken from trenches. The current mechanical trenching program has been very successful in extending previously known zones of mineralization, exposing apparent full widths, and providing excellent outcrops for geologic mapping.
E ZONE
Results from ten mechanical trenches recently completed on the E Zone are summarized below:
SUMMARY
SAMPLE
LINE
INTERVAL
(m)
AVERAGE
GOLD (G/T)
AVERAGE
SILVER (G/T)
37 3 5.90 45.7
38 3 22.42 72.0
39 4 13.88 67.0
40 3 16.07 86.0
41 3 6.01 51.0
42 2 13.42 62.0
43 3 8.81 46.0
44 2 1.29 15.0
45 2 2.60 19.0
46 4
includes 3
4.96
6.25
34.0
43.0
The E Zone has now been explored by trenching for a strike length of approximately 150 metres, and is open along strike in both directions. The E Zone is assumed to be a structural continuation of A Zone, 350 metres to south. The area between the A and E Zones is mainly covered by overburden and continuation of mineralization between the two zones has not been demonstrated. However, recent road construction has exposed a narrow, yet strongly altered and weakly gold anomalous rhyolite dike, usually associated with mineralization, between the two zones. The Company plans additional trenching in this area in the near future.
Previously announced intervals from hand trenching of the E Zone are:
SAMPLE
LINE
INTERVAL
(m)
AVERAGE
GOLD (G/T)
AVERAGE
SILVER (G/T)
14 5 13.07 91.4
15 7 5.69 38.1
16 2 15.93 132.0
17 2 2.18 19.0
A ZONE
The A Zone has now been explored by trenching and underground sampling over a strike length of approximately
100 metres, and appears to be open in both directions along strike. Trenches to the north and south of the zone
failed to penetrate post-mineral cover; however, old underground workings in the area of these trenches returned
high grade gold values. Results have been received from two additional mechanical trench sample lines at the A
Zone with results as follows:
SUMMARY
SAMPLE
LINE
INTERVAL
(m)
AVERAGE
GOLD (G/T)
AVERAGE
SILVER (G/T)
23 NSV NSV
32 4 0.920 30.5
Previously announced sample lines from the A Zone are:
SAMPLE
LINE
INTERVAL
(m)
AVERAGE
GOLD (G/T)
AVERAGE
SILVER (G/T)
1 2 18.88 168.0
2 3 27.00 145.3
24 6 27.04 702.2
25 2 9.12 157.0
26 3 56.93 261.7
27 6 16.09 114.0
28 4 10.43 77.75
29 3 13.26 119.0
30 2 17.03 98.0
31 1 3.43 54.0
Current work at El Tesoro is designed to give Northair the data and infrastructure necessary to optimize a drilling program set to commence in the first quarter of 2004. A summary news release, including pending results from the current program, will be issued following compilation and interpretation by exploration staff. The exploration program is under the direction of Mr. Jim Robinson, Vice President of the Company, who is a Qualified Person as defined by NI 43-101. Assaying to date has been performed by ALS Chemex Laboratories in Vancouver with sample preparation at their facilities in Hermosillo, Mexico. Gold assays are performed on a 50 gram fire assay using an atomic “AAS” or gravimetric finish. The Company maintains a quality control program in the preparation, shipping and checking of all samples from the property.
ON BEHALF OF THE BOARD,
INTERNATIONAL NORTHAIR MINES LTD.
__”Fred G. Hewett”__________
In our November 24, 2003 Junior Mining Exploration Weekly, we outlined the exploration merits of the El Tesoro gold/silver project held by International Northair Mines (INM : TSX-V : $1.15). The property is 100% held and located in Durango State, Mexico, and the geologic target is that of a low-sulphidation epithermal gold/silver prospect. Exploration has identified seven zones that may be geologically related to one another. A total of 474 rock chip samples taken from all seven zones prior to December yielded an average grade of 5.1 g/t Au and 37.3 g/t Ag. Just prior to Christmas, the company reported initial results from an ongoing mechanical trenching program.
International Northair is in the process of building road access to the seven zones in order to complete further trenching and to construct drill pad sites for a Q1/04 planned program. The results of the initial mechanical trenches within the A Zone have confirmed the higher-grade chip results. Some of the better reported assays included six metres at 27.0 g/t Au and 702.2 g/t Ag and three metres of 56.9 g/t Au and 261.7 g/t Ag.
Additional trenching results are anticipated this month and we estimate that an initial 3000-metre drill program could start-up as early as February. We view this junior, with a market capitalization of $15 million, as a SPECULATIVE BUY. The share price has appreciated by about 100% since our November comment. Canaccord has acted as agent in a recent equity issue for International Northair.
Canaccord
But the options are good for 5 years. I doubt the Canadian .16 will matter that much when he decides to exercise them.
I really wish I had taken out the 1.03's when I had my bid sitting at 1.02 the other day. I guess I'll have to wait for the next opportunity.
news release- I/R manager hired and in at C$1.20 for 20K, betcha he wishes he had started work yesterday to be in at C$1.04...
James R. Paterson Appointed Manager, Corporate Development
International Northair Mines Ltd. (TSXV:INM) is pleased to announce the appointment of James R. (Jim) Paterson as Manager, Corporate Development. Mr. Paterson spent over 3 years as Director of Investor Relations for an US based AMEX listed Mining Corporation along with more than 6 years investor relations experience with several North American mineral exploration companies. He has worked with The Northair Group for the last two years in a variety of roles, gaining an understanding of the group’s goals, stakeholders and business model. His role while working for public companies has been focused on expanding shareholder bases and increasing companies’ public profiles in an effort to maximize shareholder value. Mr. Paterson’s sales functions have included identifying potential buyers and forming a joint venture distribution partnership for a US-based industrial mineral producer. Jim has extensive experience coordinating marketing materials including; corporate web sites, shareholder’s reports, press releases and product brochures.
International Northair Mines Ltd. (TSXV:INM) announces that it has, pursuant to its Stock Option Plan, granted options to purchase an aggregate of 20,000 common shares. The options are exercisable on or before January 8, 2009 at an exercise price of $1.20.
ON BEHALF OF THE BOARD,
INTERNATIONAL NORTHAIR MINES LTD.
__”Fred G. Hewett”__________
Odd. I would think that you'd be better off with a good explorer should there be a downturn in gold.
Anyway, sell some more Tom, I know you have lots and like I said, I only got a partial fill. (g)
got filled at C$1.04
chart does not look that great, but the fundamentals are quite attractive, IMO... hope we don't fill that gap back down to under C$.80... but would likely buy more if it goes under C$.90...
decided to go ahead and buy anyway based on the likely news release on more trench results due in next 7-10 days... that may get some more investors lathered up...
I sold a few today. <ng> Wanted something with a resource already in case of a down turn.
I added a few myself today. Partial fill at $1.02.
EDIT: Thanks for the update!
INM about 75% finished in its road building at El Tesoro. Roads are needed to get to the trenches and future drill holes. Should have additional trenching results/news release in next 7 to 10 days. News releases on trenching will be released zone by zone.
Game plan is to finish constructing the roads and continue mechanical and hand trenching while performing "detailed geologic mapping and sampling".
Will start drilling holes in mid to late February to prove up trench results. INM is not sure how many holes will be drilled yet since this will be largely determined by the roads built, mapping, and trench results, but should be around or over 20 holes. Holes are only 200' to 400' deep, so not an expensive drill program and road construction expenses will likely exceed drill expenses, i.e. INM should have enough cash without PP anytime soon. Initial drill hole results should be in a late March news release, and like trenching, will be released on a zone by zone basis over several weeks.
Based solely on the very positive trenching results ( http://www.northair.com/international/news_releases/pr122303inm.html ), it seems a reasonably safe bet to assume the drill hole results will be quite favorable as well. Accordingly, I added about 1/3 to my position today. INM should reach C$2 per share IMO over the next 90 days, given that POG does not fall off a cliff...
FWIW, on INM's other property (in Durango), there is a chance that some CKG publicity may rub off on INM and vice versa as both companies have mines in near proximity to one another... CKG's Cucaracha Dorado property is located 20km or so from INM's, in Durango State.
See prior post http://www.investorshub.com/boards/read_msg.asp?message_id=1619797 which seems to indicate everything going as expected...
International Northair Mines Ltd.: High Grade Trenching Results Received From El Tesoro Includes 6.0 Metres of 27.04 G/T Gold and 702.2 G/T Silver
Tuesday December 23, 11:42 am ET
VANCOUVER, British Columbia--(BUSINESS WIRE)--Dec. 23, 2003--International Northair Mines Ltd. (TSX VENTURE:INM - News) has received initial mechanical trenching results from the El Tesoro Project, Durango State, Mexico. These results, in conjunction with the current exploration program, have further reinforced the property's exploration potential. At El Tesoro, Northair controls a contiguous land package of approximately 1000 hectares, covering 7 currently known gold bearing zones. (See Company Website for maps and photos). Previous hand trenching and sampling of these zones by the Company has returned significant gold values over appreciable widths.
The current mechanical trenching program has been very successful in extending previously known zones of mineralization, exposing full widths, and providing excellent outcrops for geologic mapping. A total of 10 mechanical trenches were completed on the A Zone, and results are listed below:
SUMMARY
--------------------------------------------------------------------
SAMPLE INTERVAL AVERAGE AVERAGE
LINE (m) GOLD (G/T) SILVER (G/T) COMMENTS
--------------------------------------------------------------------
23 Pending Results pending
--------------------------------------------------------------------
24 6 27.04 702.2 No bedrock exposed
within two portions of
trench.(1) True
mineralized section
estimated to be
9 metres wide.
--------------------------------------------------------------------
25 2 9.12 157.0 Additional sample
results pending
--------------------------------------------------------------------
26 3 56.93 261.7 Open to east
--------------------------------------------------------------------
27 6 16.09 114.0 Open to east
includes 4 22.60 149.0
--------------------------------------------------------------------
28 4 10.43 77.5 No bedrock exposed
for 1.5 metres within
trench.(1) True width
estimated to be 5.5
metres. Additional lower
grade mineralization (less
than 2 g/t gold) open
to east
--------------------------------------------------------------------
29 7 8.24 77.7 Lower grade (less than
2 g/t gold)
mineralization
includes 3 13.26 119.0 open to east
--------------------------------------------------------------------
30 10 5.08 52.3
includes 2 17.03 98.0
--------------------------------------------------------------------
31 1 3.43 54.0
--------------------------------------------------------------------
32 Pending Results pending
--------------------------------------------------------------------
(1) Excavator did not reach bedrock in certain portions of trench.
The trenching program within the A zone was completed over an approximate strike distance of 90 metres. Additional trenches along strike to the north and south of the zone failed to penetrate post-mineral cover. The trenches exposed higher grade gold mineralization, grading into lower grades (less than 2.0 g/t gold) over a much greater width than previously anticipated. In addition, significantly higher grade silver mineralization was encountered.
Since October, Northair has built and improved access roads, conducted mechanical and additional hand trench sampling in 4 of the 7 known zones, and collected an additional 284 samples to supplement the 474 samples previously taken by the Company. Utilizing an excavator and two caterpillar tractors, new roads have been constructed to provide access to the A, D, and E Zones as well as the upper portions of the B and C Zones. Mechanical trenching has been undertaken on the A and E Zones, while additional hand trenching has been completed on the B and C Zones where topography limits access to the excavator. A road is currently under construction to provide access to the G Zone and old underground mine workings at the B Zone. Detailed geologic mapping and sampling, which is ongoing, has been conducted in conjunction with the road building and trenching. The current program is designed to give Northair the data and infrastructure necessary to optimize drilling set to commence early in 2004. Results from the program will be released as assays are received.
As well as its ongoing project work, the Company is continuing the ongoing generative exploration program in Mexico and is presently assessing other opportunities for acquisition.
ON BEHALF OF THE BOARD,
INTERNATIONAL NORTHAIR MINES LTD.
Fred G. Hewett, President
http://biz.yahoo.com/bw/031223/235250_1.html
"downside looks limited...but then so does the upside"
Only until they drill. When they announce drilling we may see the stock appreciate and then with results, it could go either way.
Ahh that is what this stock is waiting for....:)
I avg down when in the 60's, downside looks limited...but then so does the upside...
McB
I've missed 2 chances to unload in the 80's now. Just watch, next time I'll sell at .84 and the stock will run over $1.00.
Through weak hands this puppy continues to disappoint. Let's hope the trenching turns it around.
:) Thanks, yes he did:):)
Cheers
from the cookie jar
I believe it was Claude who said " you're a smart cookie Eva"
I wanted to add a week ago but decided not to. I'm regretting it now.
Yes, same with me,I added yesterday a fairly large amount, that will help :):)
INM is at .70 Cdn for the first time in a long time.
I've been underwater with this one for a while now. Maybe the tide has finally turned.
International Northair Mines Ltd. (TSXV:INM) has regained a 100% interest in the Sierra Rosario property, Sinaloa State, Mexico, by giving notice of default to the property optionee. Sierra Rosario is known to contain six separate zones of gold and silver mineralization and was staked by Northair in 2002 as a result of its generative mineral exploration program.
Exploration by Northair on the property concentrated on the San Rafael Zone where geological mapping and sampling has defined mineralization over an area of approximately 200 by 70 metres within an intensely altered rhyolite porphyry. Twenty-three samples from this zone averaged 181 g/tonne silver and 0.321 g/tonne gold over average widths of approximately 15 metres. This sampling indicates the potential for a bulk tonnage silver/gold deposit and additional work is warranted to further test this potential. Further exploration is also justified on Sierra Rosario’s remaining five zones, where initial sampling has returned gold values up to 5.48 g/tonne from grab samples.
Northair now has four prospective properties with multiple precious metal targets located in the Mexican Sierra Madres. A mechanical trenching program continues at the El Tesoro Project to further define targets for an upcoming drill program. Planning is also underway for an initial program at the recently acquired Las Moras Project.
In corporate matters, Northair has granted options of 100,000 shares at $0.69 to employees of the Company.
ON BEHALF OF THE BOARD,
INTERNATIONAL NORTHAIR MINES LTD.
INM news
Northair Acquires Additional Mexican Property
International Northair Mines Ltd. (TSXV:INM) is pleased to announce that the Company has acquired an additional property located in the state of Durango, Mexico. The “Las Moras” Project is located in the Sierra Madre Mountains, pproximately 100 kilometers east of Mazatlan, and 120 kilometers southwest of the city of Durango. Las Moras lies in a geologic setting similar to the Company’s El Tesoro property, and has the potential to contain high grade gold as well as bulk tonnage base metal deposits.
Las Moras was identified by Company geologists during Northair’s ongoing generative exploration program. High grade, low sulfidation gold veins have been discovered in limited outcrops. First phase sampling from these gold veins by the Company has reported very encouraging results, with four grab samples averaging 18.39 g/t gold and 7.88 g/t silver. Due to the limited outcrop, true widths and strike lengths of these zones have yet to be determined and a hand trenching program will be initiated shortly. Although there are no known historic mines on the property, numerous small gambusino workings and arrastras have been observed in the area of the high grade veins.
A separate zone of copper-lead-zinc mineralization was discovered by Company geologists during their property examination. The width of the mineralized zone where observed, averages about 30 meters and has been traced on the ground during initial field visits for over 300 meters along strike length, and is open in both directions. Four representative grab samples from this zone averaged 0.35% copper, 0.26% lead, and 0.96% zinc. These results are considered very significant in an oxidized environment.
The Las Moras property is comprised of optioned and wholly owned concessions totaling 450 hectares. Northair has signed an option agreement, subject to due diligence, to acquire 100% of a privately held concession with staged payments totaling US $86,000 over a four year period. There are no royalties. The Company has also staked concessions covering highly prospective ground adjacent to the privately held concession. Detailed exploration of the property will commence in early November with a program of geological mapping, sampling and hand trenching to be followed by mechanical trenching. Project access is good with numerous unimproved old logging roads located in the area.
At the Company’s El Tesoro Project, an exploration program is well underway. Road building, mechanical trenching, sampling and geological mapping are progressing in preparation for a drilling program. As well as the exploration program underway on our El Tesoro Project, and the planned program at Los Moras, the Company is continuing with its aggressive generative exploration program. Currently a number of projects are under review for possible acquisition. The Company is very excited about its opportunities in Mexico and looks forward to providing shareholders with additional information as it becomes available.
ON BEHALF OF THE BOARD,
INTERNATIONAL NORTHAIR MINES LTD.
There's no reason for this stock to go down other than the delay in drilling. The fundamentals are as good as ever
-Low shares outstanding
-Well financed
-Excellent property in Mexico that has never been mined/drilled
If it hits .60 I will have to add more.
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
117
|
Created
|
07/08/03
|
Type
|
Free
|
Moderators |
Inmed Pharmaceuticals (IMN) Company Spotlight
A drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids. InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed is utilizing its proprietary bioinformatics assessment tool to identify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases. The goal is to identify new drug candidates that optimize therapeutic benefit while limiting adverse effects. InMed’s proprietary in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.
Investment Highlights
Bioinformatics: Proprietary Drug / Disease Targeting Tool
InMed’s has developed a computer-based program to assist in the identification of novel cannabinoids using: (i) comprehensive algorithms to integrate data from numerous bioinformatics databases, (ii) a database on the structure of currently approved pharmaceutical products, and (iii) an extensive database on over 90 individual cannabinoid drugs found in cannabis. InMed’s data included in its bioinformatics assessment tool are derived from both public and propriety based sources and include information on: Protein-Protein interactions, Gene Regulation, Epigenetic modification, Cell signal networks, and Metabolomics
Biosynthesis
Most of us are familiar with the two main bio-active ingredients produced by the cannabis (marijuana) plant, namely THC and CBD. In reality, however, there are 90+ cannabinoids in the plant that could have medical value but are too hard to research due to the fact that they only appear in trace amounts in each plant. InMed has developed, patented, and intends to commercialize a process for producing all 90+ cannibinoids using genetically engineered bacteria to create bioidentical copies of these substances. Not only is their process less costly but it also produces these cannabinoids in large quantities at pharmaceutical-grade purity. The following link provides a clear explanation of the process in laymen's terms.
Biosynthesis: The Science That May Unlock the Medical Potential of Cannabis
InMed is building a robust product pipeline through its proprietary discovery platform and research & product development programs. The company continues to seek innovative product candidates for the treatment in following therapeutic areas:
|
|
InMed's pipeline currently includes two drug candidates in preclinical development: INM-750 for the treatment of epidermolysis bullosa (EB); and INM-085 for the treatment of glaucoma.
INM-750
Referred to as "The Worst Disease You've Never Heard Of," EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. Through the development of INM-750, InMed is attempting to address this significant unmet medical need, for which there is no approved treatment or cure. INM-750 replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.
Market Potential - Amicus Therapeutics recently acquired Scioderm, Inc. and its lead EB drug candidate, Zorblisa™, for $847 million. Notably, Scioderm's sole clinical asset was Zorblisa.
JP Morgan and Cowen Research Reports estimate that peak sales for Zorblisa could reach $900 million to $1.2 billion.
INM-085
INM-085 is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure.
Market Potential - The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease. Worldwide, glaucoma represents a market of $5.6 billion.
Leadership
InMed's management team has well over a century of combined experience in the biopharmaceutical space. Together, the professionals comprising this team are guiding InMed into exciting opportunities in the cannabis-pharma sector.
Eric A. Adams, President & CEO
Eric Adams is a seasoned biopharmaceutical executive with over 25 years of experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs.
He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana aerospace industry, most recently with Metal Form, Inc., a privately held aerospace manufacturing company, where he served as president and CEO from 1987 to September of 1999.
Dr. Sazzad Hossain, Ph.D., M.Sc., Chief Scientific Officer
Dr. Sazzad Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.
Dr. Ado Muhammed, MD, DPM, MFPM, Chief Medical Officer
Dr. Ado Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs. His previous position was Associate Medical Director at GW Pharmaceuticals, a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role and others at GW Pharmaceuticals, Dr. Muhammed was involved in the advanced delivery of core clinical research and was involved in key decision-making regarding R&D and product commercialization. Dr. Muhammed's received his MD at Ahmadu Bello University followed by an MSc in Orthopaedics at University College London. Dr. Muhammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff followed by an MBA in Business Administration at the University of Leicester. He is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.
Alexandra D.J. Mancini, M.Sc., Senior Vice President, Clinical and Regulatory Affairs
Alexandra Mancini has over 30 years' of global biopharmaceutical R&D experience with a particular emphasis on clinical development and regulatory affairs. Ms. Mancini has been an executive with several biotech companies, overseeing a wide range of drug development activities. As Sr. VP of Clinical & Regulatory Affairs at Sirius Genomics, her role included identifying and managing external resources for medical expertise in sepsis; clinical data management; and statistical theory, programming and analyses. While at INEX Pharmaceuticals as Sr. VP of Clinical & Regulatory Affairs, Ms. Mancini oversaw Clinical Research, Medical Affairs, Clinical Data Management, Medical Writing, Regulatory Affairs, and Quality Assurance for oncology. She served as VP of Regulatory Affairs at QLT Inc. for oncology and ocular diseases, playing a significant role in the development of VISUDYNER from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Ms. Mancini also led the regulatory approval process for the anticancer drug PHOTOFRINR and its associated medical devices, the first drug-device combination product approved by the US Food and Drug Administration. Ms. Mancini has led the data analysis and assimilation, writing, submission and subsequent defense of drug submissions to regulatory agencies around the world, leading to several drug approvals and label extensions. Ms. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business, Simon Fraser University.
Jeff Charpentier, CFO, Chief Financial Officer
Jeff Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of $150M and concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.
InMed Pharmaceuticals, Inc. | NetworkNewsWire |
NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website: https://www.networknewswire.com/disclaimer/
InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
Corporate Presentation
https://www.inmedpharma.com/site/assets/files/1343/jan-cp-2017-2.pdf
InMed Pharmaceuticals is currently developing two products in its drug pipeline: INM-750, for the treatment of Epidermolysis Bullosa, and INM-085, for the treatment of Glaucoma.
Epidermolysis Bullosa (EB) is group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears easily from friction or trauma. Internal organs and bodily systems can also be affected by EB. It is a result in a defect of anchoring between the dermis and epidermis cause most frequently by the absence of certain keratins (or, proteins) in the skin. EB is an orphan disease with no currently approved treatments and has a significant unmet medical need. INM-750 will potentially be the first therapy designed and developed specifically to modulate disease activity and to alleviate symptoms in EB.
INM-750 includes multiple cannabinoids as the active ingredients:
INM-085
Glaucoma is a group of eye disorders which result in damage of the optic nerve. The damage is most often caused by an abnormally high pressure in the eye and is one of the leading causes of blindness in the developed world.
INM-085 will be the first ever glaucoma treatment developed that is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy. The cannabinoids in INM-085 have been selected to reduce the elevated intra-ocular pressure (IOP) in the affected eyes and provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues. INM-085 is designed as a topical formulation to be administered directly to the eye. The formulation that has been designed by InMed is a proprietary polymer-based formulation to facilitate absorption of the cannabinoids into the eye while also being well tolerated by the patients. We envision a once-a-day application, at bedtime, to deliver effective dose levels of INM-085.
Proposed Targets to Develop Drugs From Cannabis and Other Botanical Sources
Dermatology
Ocular
Pain and Inflammation
CNS
Respiratory
Metabolic Disease
The majority of pharmaceutical and academic research & development activities being performed with cannabis revolves around the understanding of its biologically active ingredients, the Cannabinoids
Currently there are 90+ cannabinoids that have been isolated from cannabis, each affecting the body’s cannabinoid receptors and responsible for unique pharmacological effects.
There are three general types of cannabinoids: herbal cannabinoids which occur uniquely in the cannabis, endogenous cannabinoids produced in the bodies of humans and animals and synthetic cannabinoids produced in the laboratory.
Cannabinoid Receptors
Before the 1980s, it was often speculated that cannabinoids produced their effects through nonspecific interaction with cell membranes, instead of interacting with specific receptors. The discovery of the first cannabinoid receptors in the 1980s helped to clarify their role. These receptors are common in animals, and have been found in mammals, birds, fish and reptiles. There are currently two known types of cannabinoid receptors, called CB1 and CB2.
CB1 receptors are found primarily in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems. CB1 receptors are essentially absent in the medulla oblongata, the part of the brain that is responsible for respiratory and cardiovascular functions. Thus, there is not a risk of respiratory or cardiovascular failure as there is with many other drugs. CB1 receptors appear to be responsible for the euphoric and anticonvulsive effects of cannabis.
CB2 receptors are almost exclusively found in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis.
The protein sequences of these two receptors are about 45% similar. In addition, minor variations in each receptor have been identified. There is some indication that other receptors exist, but none have been confirmed. Cannabinoids bind reversibly and stereo-selectively to the cannabinoid receptors. The affinity of an individual cannabinoid to each receptor determines the effect of that cannabinoid. Cannabinoids that bind more selectively to certain receptors are more desirable for medical usage.
Herbal Cannabinoids
Herbal cannabinoids are nearly insoluble in water but soluble in lipids, alcohols and other non-polar organic solvents. All herbal cannabinoids are derived from their respective 2-carboxylic acids (2-COOH) by decarboxylation that is, catalyzed by heat, light, or alkaline conditions. Herbal cannabinoids occur naturally only in the cannabis plant, and are concentrated in a viscous resin that is produced in glandular structures known as trichomes. In addition to cannabinoids, the resin is rich in terpenes, which are largely responsible for the odor of the cannabis plant.
There are over ninety known herbal cannabinoids. Of these, tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prevalent and have received the most attemtion. Other common cannabinoids include:
CBG | Cannabigerol |
CBC | Cannabichromene |
CBL | Cannabicyclol |
CBN | Cannabidiol |
CBV | Cannabivarol |
THCV | Tetrahydrocannabivarin |
CBDV | Cannabidivarin |
CBCV | Cannabichromevarin |
CBGV | Cannabigerovarin |
CBGM | Cannabigerol Monoethyl Ether |
THC is the primary psychoactive component of the plant. Medically, it appears to mediate pain and to be neuroprotective. THC has a greater affinity for the CB1 receptor than for the CB2 receptors. Its effects are perceived to be more cerebral. CBD is not psychoactive, and appears to mediate the euphoric effect of THC. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver. Medically, it appears to relieve convulsion, inflammation, anxiety, and nausea. CBD has a greater affinity for the CB2 receptor than for the CB1 receptor. It is perceived to have more effect on the torso than on the brain or CNS. Cannabinoids were first discovered in the 1940s. The structure of THC was first determined in 1964. Due to molecular similarity and ease of synthetic conversion, it was originally believed that CBD was a natural precursor to THC. However, it is now known that CBD and THC are produced independently in the cannabis plant. Cannabis plants can exhibit wide variation in the quantity and type of cannabinoids they produce. The mixture of cannabinoids produced by a plant is known as the plant’s cannabinoid profile. Selective breeding has been used to control the genetics of plants and modify the cannabinoid profile. For example, strains of hemp, which are used as fiber, are bred such that they are low in psychoactive chemicals like THC. Strains used in medicine are often bred for high CBD content, and strains used for recreational purposes are usually bred for high THC content, or for a specific chemical balance. Some strains of more than 20% THC have been created. Cannabinoids can be administered by: smoking, vaporizing, oral ingestion, transdermal patch, intravenous injection, sublingual absorption, or rectal suppository. Once in the body, most cannabinoids are metabolized in the liver, although some is stored in fat. Cannabinoids can be separated from the plant by extraction with organic solvents. However, to produce high purity, cannabinoid chemical synthesis or semisynthesis is generally required.
University of British Columbia
Department of Chemical & Biological Engineering
Vancouver Campus
2360 East Mall
Vancouver, BC Canada V6T 1Z3
Department of Pharmaceutical Sciences
Vancouver Campus
2405 Westbrook Mall
Vancouver, BC, Canada V6T 1Z3
University of Debrecen
Research Center for Molecular Medicine, Department of Physiology
1H-4032 Debrecen, Nagyerdei krt. 98
Hungary
ALERT
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |